Enoxaparine Becat 6000 IU (60 mg)/0,6 ml inj. sol. i.v./s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 6000 iu (60 mg)/0,6 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 10000 - solution for injection in pre-filled syringe - 6000 iu (60 mg)/0,6 ml - enoxaparin sodium 10000 iu/ml - enoxaparin

Enoxaparine Becat 8000 IU (80 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 8000 iu (80 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 10000 - solution for injection in pre-filled syringe - 8000 iu (80 mg)/0,8 ml - enoxaparin sodium 10000 iu/ml - enoxaparin

Enoxaparine Becat 10000 IU (100 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 10000 iu (100 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 10000 - solution for injection in pre-filled syringe - 10000 iu (100 mg)/1 ml - enoxaparin sodium 10000 iu/ml - enoxaparin

Enoxaparine Becat 12000 IU (120 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 12000 iu (120 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 15000 - solution for injection in pre-filled syringe - 12000 iu (120 mg)/0,8 ml - enoxaparin sodium 15000 iu/ml - enoxaparin

Enoxaparine Becat 15000 IU (150 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

enoxaparine becat 15000 iu (150 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr.

laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 15000 - solution for injection in pre-filled syringe - 15000 iu (150 mg)/1 ml - enoxaparin sodium 15000 iu/ml - enoxaparin

Enoxaparin Sandoz 2000 IU (20 mg) 0.2 mL Solution for Injection in Pre-filled Syringe マレーシア - 英語 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

enoxaparin sandoz 2000 iu (20 mg) 0.2 ml solution for injection in pre-filled syringe

novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -

Enoxaparin Sandoz 4000 IU (40 mg) 0.4 mL Solution for Injection in Pre-filled Syringe マレーシア - 英語 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

enoxaparin sandoz 4000 iu (40 mg) 0.4 ml solution for injection in pre-filled syringe

novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -

Enoxaparin Sandoz 6000 IU (60 mg) 0.6 mL Solution for Injection in Pre-filled Syringe マレーシア - 英語 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

enoxaparin sandoz 6000 iu (60 mg) 0.6 ml solution for injection in pre-filled syringe

novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -

ENOXAPARIN SODIUM injection アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

enoxaparin sodium injection

watson pharma, inc. - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium 30 mg in 0.3 ml

ENOXAPARIN SODIUM injection アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

enoxaparin sodium injection

cardinal health - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): enoxaparin sodium is indicated for: enoxaparin sodium is indicated for the prophylaxis of ischemic complications of unstable angina and non–q-wave myocardial infarction, when concurrently administered with aspirin. enoxaparin sodium, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute st-segment elevation myocardial infarction (stemi) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (pci). enoxaparin sodium is contraindicated in patients with: risk summary placental transfer of enoxaparin was observed in the animal studies. human data from a retrospective cohort study, which included 693 live births, suggest that enoxaparin does not increase the risk of major developmental abnormalities (see data) . based on animal data, enox